These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10593925)

  • 1. Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI.
    Bielicki J; Crawley AC; Davey RC; Varnai JC; Hopwood JJ
    J Biol Chem; 1999 Dec; 274(51):36335-43. PubMed ID: 10593925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.
    Brooks DA; King BM; Crawley AC; Byers S; Hopwood JJ
    Biochim Biophys Acta; 1997 Aug; 1361(2):203-16. PubMed ID: 9300802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
    Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
    Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
    Auclair D; Hein LK; Hopwood JJ; Byers S
    Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI.
    Byers S; Nuttall JD; Crawley AC; Hopwood JJ; Smith K; Fazzalari NL
    Bone; 1997 Nov; 21(5):425-31. PubMed ID: 9356736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feline mucopolysaccharidosis type VI: correction of glycosaminoglycan storage in myoblasts by retrovirus-mediated transfer of the feline N-acetylgalactosamine 4-sulfatase gene.
    Yogalingam G; Bielicki J; Hopwood JJ; Anson DS
    DNA Cell Biol; 1997 Oct; 16(10):1189-94. PubMed ID: 9364929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
    Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
    Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
    Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
    Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease.
    Yogalingam G; Litjens T; Bielicki J; Crawley AC; Muller V; Anson DS; Hopwood JJ
    J Biol Chem; 1996 Nov; 271(44):27259-65. PubMed ID: 8910299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency.
    Byers S; Crawley AC; Brumfield LK; Nuttall JD; Hopwood JJ
    Pediatr Res; 2000 Jun; 47(6):743-9. PubMed ID: 10832731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.
    Auclair D; Hopwood JJ; Brooks DA; Lemontt JF; Crawley AC
    Mol Genet Metab; 2003 Mar; 78(3):163-74. PubMed ID: 12649061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
    Turner CT; Hopwood JJ; Bond CS; Brooks DA
    Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
    Crawley AC; Niedzielski KH; Isaac EL; Davey RC; Byers S; Hopwood JJ
    J Clin Invest; 1997 Feb; 99(4):651-62. PubMed ID: 9045867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.
    Crawley AC; Yogalingam G; Muller VJ; Hopwood JJ
    J Clin Invest; 1998 Jan; 101(1):109-19. PubMed ID: 9421472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.
    Crawley AC; Brooks DA; Muller VJ; Petersen BA; Isaac EL; Bielicki J; King BM; Boulter CD; Moore AJ; Fazzalari NL; Anson DS; Byers S; Hopwood JJ
    J Clin Invest; 1996 Apr; 97(8):1864-73. PubMed ID: 8621770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of N-acetylgalactosamine 4-sulfatase expression in retrovirus-transduced feline mucopolysaccharidosis type VI muscle cells.
    Yogalingam G; Muller V; Hopwood JJ; Anson DS
    DNA Cell Biol; 1999 Mar; 18(3):187-95. PubMed ID: 10098600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats.
    Ponder KP; O'Malley TM; Wang P; O'Donnell PA; Traas AM; Knox VW; Aguirre GA; Ellinwood NM; Metcalf JA; Wang B; Parkinson-Lawrence EJ; Sleeper MM; Brooks DA; Hopwood JJ; Haskins ME
    Mol Ther; 2012 May; 20(5):898-907. PubMed ID: 22395531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.